Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BiPar Sciences has expanded its clinical trials program through the initiation of an additional Phase II study of its lead product candidate BSI-201.
Subscribe to our email newsletter
The trial will assess BSI-201, the first ADP-ribose polymerase (PARP) inhibitor in the company’s DNA repair portfolio, for the treatment of uterine carcinosarcoma or malignant mixed mullerian tumors. The primary objective of this trial is to determine the antitumor activity of BSI-201 plus carboplatin/paclitaxel in patients with recurrent or advanced uterine carcinosarcomas.
This multi-center, open-label, single-arm study in patients with recurrent or advanced uterine carcinosarcomas will evaluate BSI-201 in combination with standard treatment. The study is being conducted by the Gynecologic Oncology Group, a National Cancer Institute-funded research organization which focuses on gynecologic malignancies.
Barry Sherman, executive vice president of BiPar, said: “This will be our third study designed around our gene expression data, which has been invaluable in selecting types of cancer that will most likely respond to PARP inhibition.”